A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of
HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and,
to assess the activity of HE3286 on insulin sensitivity and hepatic glucose production in
obese insulin-resistant adult subjects.